Huons said it would supply its local anesthetic product to McKesson, a U.S. drug distribution company, through its U.S. subsidiary Huons USA.

Under the accord, Huons plans to export a “5mL vial of 1 percent lidocaine hydrochloride injection,” which received U.S. Food and Drug Administration’s Abbreviated New Drug Application (ANDA) approval in 2020.

Huons expects to expand trust and influence in its products through this contract, while McKesson plans to promote the high quality of Korean injectables through its large-scale distribution network.

Huons stressed that this contract could become possible through the suggestion of McKesson, which showed interest in Korean injections. The company added that it would contribute to resolving the continuing shortage of basic medicines in the U.S., as lidocaine injection has been in chronic supply shortage in America since the 2010s.

Huons also plans to expand its product lineup targeting the U.S. market based on this contract.

“We could sign the supply contract with McKesson, thanks to our unique strength, technology, and quality that allowed us to receive approval from the FDA for four items -- saline solution, Bupivacaine injection, Lidocaine Injection 1 percent ample, and vial,” a company official said. “With this contract as a starting point, we expect that Huons' position in the North American basic injection market will become stronger.”

The official added that the company would take the lead in promoting the potential of domestic injections to the global market by promptly promoting the FDA approval process for additional items under discussion.